Spiderwort Inc. has announced the closing of their $2.5 million USD Series Seed round financing. This round of funding will allow the company to continue its work towards clinical trials that are key to bringing their biomaterial to market.
The financing was led by Horizons Ventures, and supported by a number of groups, most notably investors from the Capital Angel Network, Break Off Capital, Anges Québec, and a U.S. syndicate.